Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2010
11/25/2010US20100298348 Method of Decreasing Ubiquitylated Protein Levels
11/25/2010US20100298345 Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
11/25/2010US20100298342 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease
11/25/2010US20100298341 Glycine Transporter-1 Inhibitors
11/25/2010US20100298340 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies
11/25/2010US20100298337 Organic Compounds
11/25/2010US20100298336 Pyrimidines as novel therapeutic agents
11/25/2010US20100298334 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
11/25/2010US20100298333 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
11/25/2010US20100298332 Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands
11/25/2010US20100298328 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes
11/25/2010US20100298326 Carboxamide compounds and their use as calpain inhibitors
11/25/2010US20100298325 Pyridine derivatives for the treatment of amyloid-related diseases
11/25/2010US20100298322 Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use
11/25/2010US20100298318 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
11/25/2010US20100298316 Benzothiazoles Having Histamine H3 Receptor Activity
11/25/2010US20100298315 Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmnaceutical compositions and novel use as met inhibitors
11/25/2010US20100298312 Substituted pyrimidinyl-amines as protein kinase inhibitors
11/25/2010US20100298310 Thiazole Derivatives as Kinase Inhibitors
11/25/2010US20100298309 Tricyclic triazolic compounds
11/25/2010US20100298308 Compositions and methods for bone formation and remodeling
11/25/2010US20100298307 Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use
11/25/2010US20100298306 (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease
11/25/2010US20100298305 Tizanidine for the treatment of post-traumatic stress disorder and nightmares
11/25/2010US20100298304 Diagnosis and treatment of autism spectrum disorders
11/25/2010US20100298303 Cgrp receptor antagonists
11/25/2010US20100298298 Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof
11/25/2010US20100298292 Modulators of 5-ht receptors and methods of use thereof
11/25/2010US20100298291 Fused bicyclic-substituted amines as histamine-3 receptor ligands
11/25/2010US20100298287 Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
11/25/2010US20100298285 Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
11/25/2010US20100298280 Compounds for the Modulation of Huntingtin Aggregation, Methods and Means for Identifying Such Compounds
11/25/2010US20100298279 Oral Contraceptives to Prevent Pregnancy and Diminish Premenstrual Symptomatology
11/25/2010US20100298278 Inhibitors of beta-secretase for the treatment of alzheimer's disease
11/25/2010US20100298274 Fat containing composition
11/25/2010US20100298273 Lipid mixture for infant nutrition
11/25/2010US20100298268 Controlled release formulations of levodopa and uses thereof
11/25/2010US20100298248 Biologically active macrolides, compositions, and uses thereof
11/25/2010US20100298230 Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders
11/25/2010US20100298227 Treatment of autoimmune conditions with Copolymer 1 and related copolymers
11/25/2010US20100298225 Peptide gap junction modulators
11/25/2010US20100298217 Csf-1r mutants
11/25/2010US20100298202 Bri polypeptides and reducing ab aggregation
11/25/2010US20100298201 Peptidomimetic macrocycles with improved properties
11/25/2010US20100298200 Compounds and assays for controlling Wnt activity
11/25/2010US20100297665 Method for testing and screening p38 map kinase modifiers
11/25/2010US20100297269 Compositions for intranasal administration
11/25/2010US20100297266 Preparations and methods for textile and or fiber surface finishing, surface finished articles prepared thereby, and uses therefor
11/25/2010US20100297240 1- [2- (2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
11/25/2010US20100297221 pharmaceutical composition of tacrolimus
11/25/2010US20100297196 Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids
11/25/2010US20100297195 Controlled release lamotrigine formulations
11/25/2010US20100297181 AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
11/25/2010US20100297160 High Molecular Weight Amyloid Beta As a Carrier for the Oral Delivery of Vaccine Antigens
11/25/2010US20100297147 Compositions and methods for modulating tlr14 activity
11/25/2010US20100297132 Monoclonal antibody
11/25/2010US20100297128 Gamma secretase modulators
11/25/2010US20100297121 Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists
11/25/2010US20100297109 Methods for inhibiting fascin
11/25/2010US20100297077 Novel aryl potassium channel blockers and uses thereof
11/25/2010US20100297070 COMPOSITIONS AND METHODS FOR AMELIORATING CNS INFLAMMATION, PSYCHOSIS, DELIRIUM, PTSD or PTSS
11/25/2010US20100297066 Biodegradable peptide releasing polymers
11/25/2010US20100297054 1,2,3-triazole derivatives for use as stearoyl-coa desaturase inhibitors
11/25/2010US20100297046 Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors
11/25/2010US20100297035 Thiazole Amides, Imidazole Amides and Related Analogues
11/25/2010US20100297032 Transdermal delivery system
11/25/2010US20100297031 Orodispersible tablets
11/25/2010US20100297013 Humanized antibody
11/25/2010DE202010008608U1 Die pharmazeutische Zusammensetzung The pharmaceutical composition
11/25/2010CA2762939A1 Self-emulsifying composition of .omega.3 fatty acid
11/25/2010CA2762853A1 Cell therapy for brain tissue damage
11/25/2010CA2762625A1 Process for the preparation of ibodutant (men15596) and related intermediates
11/25/2010CA2762577A1 Novel pharmaceutically acceptable salts of 4-(1h-imidazol-4-ylmethyl)pyridine and their therapeutical uses
11/25/2010CA2762226A1 Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors
11/25/2010CA2761961A1 Modulators of 5-ht receptors and methods of use thereof
11/25/2010CA2761624A1 Compositions for continuous administration of dopa decarboxylase inhibitors
11/24/2010EP2253646A1 Anti-dual integrin antibody and compositions and conjugates comprising said antibody
11/24/2010EP2253636A1 Neuronal cell death inhibitor
11/24/2010EP2253631A1 Spyrocyclic quiniclidinic ether derivatives
11/24/2010EP2253618A1 Compound having 6-membered aromatic ring
11/24/2010EP2253616A1 Process for the preparation of compounds capable of activating cholinergic receptors
11/24/2010EP2253327A1 Pharmaceutical composition containing a compound having angiotensin II antagonistic activity in combination with another compound
11/24/2010EP2253313A1 Tranilast as modulator of T cell functioning for use in the treatment of autoimmune diseases
11/24/2010EP2252633A1 Anti-trka antibodies and derivatives thereof
11/24/2010EP2252612A1 Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
11/24/2010EP2252608A1 Method for treating pain syndrome and other disorders
11/24/2010EP2252603A1 The hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
11/24/2010EP2252599A1 Triazole amide derivatives for use in therapy
11/24/2010EP2252596A1 Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings
11/24/2010EP2252593A1 Substituted pyridazine derivatives which have histamine h3 antagonist activity
11/24/2010EP2252591A1 Aryl-substituted imidazolidine-2,4-diones, method for the production thereof, medicaments containing said compounds and use thereof
11/24/2010EP2252589A2 6-and 7-amino isoquinoline compounds and methods for making and using the same
11/24/2010EP2252587A1 Piperidine sulfonamide derivatives
11/24/2010EP2252581A1 Kappa selective opioid receptor antagonist
11/24/2010EP2252578A1 Novel conjugates for treating neurodegenerative diseases and disorders
11/24/2010EP2252573A2 New polymorph and amorphous forms of desvenlafaxine fumarate
11/24/2010EP2252372A1 2-aminoquinolines
11/24/2010EP2252310A1 Heterocyclic peptide ketoamides
11/24/2010EP2252305A2 Omentum and use thereof
11/24/2010EP2252299A1 Fused pyridone m1 receptor positive allosteric modulators
1 ... 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 ... 1833